Non-Systemic Drugs: A Critical Review by Charmot, Dominique
1434  Current Pharmaceutical Design, 2012, 18, 1434-1445  
  1873-4286/12 $58.00+.00   © 2012 Bentham Science Publishers 
Non-Systemic Drugs: A Critical Review 
Dominique Charmot* 
Ardelyx, Inc., 34175 Ardenwood Blvd, Fremont, CA 94555, USA 
Abstract: Non-systemic drugs act within the intestinal lumen without reaching the systemic circulation. The first generation included po-
lymeric resins that sequester phosphate ions, potassium ions, or bile acids for the treatment of electrolyte imbalances or hypercholestere-
mia. The field has evolved towards non-absorbable small molecules or peptides targeting luminal enzymes or transporters for the treat-
ment of mineral metabolism disorders, diabetes, gastrointestinal (GI) disorders, and enteric infections. From a drug design and develop-
ment perspective, non-systemic agents offer novel opportunities to address unmet medical needs while minimizing toxicity risks, but also 
present new challenges, including developing a better understanding and control of non-transcellular leakage pathways into the systemic 
circulation. The pharmacokinetic-pharmacodynamic relationship of drugs acting in the GI tract can be complex due to the variability of 
intestinal transit, interaction with chyme, and the complex environment of the surface epithelia. We review the main classes of non-
absorbable agents at various stages of development, and their therapeutic potential and limitations. The rapid progress in the identifica-
tion of intestinal receptors and transporters, their functional characterization and role in metabolic and inflammatory disorders, will un-
doubtedly renew interest in the development of novel, safe, non-systemic therapeutics. 
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1. INTRODUCTION 
  Non-absorbable drugs are a unique subset of orally adminis-
tered agents that exert their therapeutic effects locally in the GI 
tract. In contrast to traditional drugs, which are designed to be rap-
idly absorbed, to achieve therapeutic plasma levels, and then be 
eliminated by multiple pathways, non-absorbable drugs are de-
signed to minimize systemic exposure. Because of these fundamen-
tal differences, the discovery and development of non-absorbable 
drugs is directed by its own unique and still-developing set of 
pharmaceutical design principles, which will be described in this 
review. We will also provide examples of the broad utility of non-
absorbable drugs, which are used extensively to treat systemic 
metabolic and mineral disorders as well as their more obvious ap-
plications to diseases of the GI tract. 
  Early examples of non-absorbable drugs were relatively unso-
phisticated cation and anion exchange resins that remove bile acids 
or potassium ions from the lumen of the gut for the treatment of 
hypercholestemia and hyperkalemia, respectively. These resins 
were grandfathered in by the Food and Drug Administration (FDA) 
in the 1960s and are still in use today. Building on these early suc-
cesses, the development of non-absorbable drugs has expanded 
greatly and now encompasses a variety of agents, polymers, small 
molecules, or peptides, acting throughout the GI tract and providing 
therapeutic benefit across a wide array of indications. In some ex-
amples the non-absorption characteristics were found serendipi-
tously, while other drugs were rationally designed for that purpose. 
A misperception about non-systemic drugs is that, because they are 
confined to the GI tract, they can only treat GI disorders: we de-
scribe in this review that the majority of uses are for treatment of 
systemic diseases such as mineral or metabolic disorders. With 
safety criteria becoming increasingly important and approval crite-
ria becoming more stringent, particularly for the treatment of 
chronic disease in large patient populations, non-systemic drugs 
offer the great advantage of minimizing off-target systemic effects 
and thereby greatly reducing risks of drug-drug interaction, toxicity, 
or side-effects. As a result the field has registered a number of in-
novative products at various stages of development using increas-
ingly sophisticated approaches. 
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 The  terms  non-systemic and non-absorbed have been used in-
terchangeably for drugs of very different absorption profiles and 
metabolism pathways, and we will use the same terms throughout 
this review. We first briefly review the main mechanisms of drug 
absorption and drug disposition of non-absorbed drugs. We then 
review existing and emerging non-systemic drugs according to their 
mode of action, targets, and therapeutic actions. 
2. CLASSIFICATION OF NON-ABSORBED DRUGS 
  In addition to being extremely diverse in nature and structure, 
non-absorbed drugs act therapeutically via various modes. We pro-
pose allocating non-systemic drugs to five classes characterized by 
common attributes schematically represented in Fig. (1), as   
follows: 
i).  Sequestering agents: their primary function is to bind a small 
molecule such as a nutrient, an endogenous ligand or a toxin in 
the lumen of the gut to form an insoluble complex ultimately 
eliminated in the feces. 
ii).  Ligands of soluble intestinale nzymes: these compounds 
target host proteins resident in the gut lumen: Representatives 
of this class are small molecules that inhibit the activity of di-
gestive enzymes (e.g. lipase, saccharidase) there by blocking 
the digestion of dietary components into readily absorbable en-
tities (e.g. triglycerides into fatty acids; dietary polysaccha-
rides into glucose, fructose and galactose), resulting in a net-
decrease in nutrient absorption. 
iii).  Enzymes: either of animal origin or recombinant proteins, 
acting in the gut lumen to compensate for an enzyme defi-
ciency in the host or to metabolize certain bacterial or meta-
bolic toxins; an example of the former is the treatment of cys-
tic fibrosis induced pancreatic insufficiency by administration 
of porcine pancreatic enzymes. 
iv).  Minimally absorbed and rapidly metabolized: these drugs 
are locally absorbed and act on targets expressed within the 
inner wall of the gut (lamina propria or myenteric muscles). 
The parent drug is quickly degraded by first-pass metabolism 
in the enterocytes and/or in the liver, with spurious low levels 
in systemic circulation. This class of drugs (also referred to as 
soft drugs) is designed to undergo rapid cleavage or conjuga-
tion by first- and second-pass metabolism, and has been re-
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v).  Ligands of apical targets: these agents specifically target 
membrane proteins expressed on the surface of the gut epithe-
lia. These compounds are non-absorbed synthetic molecules or 
peptides fulfilling a variety of functions, including inhibiting 
transporters and channels, binding to G-Protein coupled-
receptors (agonists and antagonists), or modulating tight junc-
tion (TJ) permeability. This class will undoubtedly expand 
given the myriad of potential targets and their potential role 
across many therapeutic areas. 
3. FACTORS GOVERNING GUT PERMEABILITY TO 
DRUGS 
  The intestinal tract is endowed with a multitude of absorption 
and sampling pathways to selectively and actively transport nutri-
ents from the lumen of the gut into the bloodstream. It is has a 
combination of passive and active transport, and efflux mechanisms 
operating at the enterocyte level [5], while other pathways involve 
M cells and dendritic cells sampling luminal entities via endocyto-
sis / pinocytosis. The absorption of systemic drugs generally pro-
ceeds by passive or active transport within the enterocytes as well 
as by passive paracellular transport through the TJs. Many phe-
nomenological approaches and attempts at modeling drug absorp-
tion in the GI tract have been reported; the most popular one is 
referred to as the Lipinski’s rule [6]. Such methods are now com-
pletely integrated in drug discovery and lead optimization methods, 
providing medicinal and computational chemists valuable semi-
empiric tools to predict the absorption of small molecules drugs. 
For instance Lipinski established a combination of criteria for mo-
lecular weight, lipophilicity, hydrogen donor-acceptors, and ro-
tatable bonds (Lipinski’s Rule of Five, or Lipinski’s Rule) that is 
judged essential for gut absorption. In this heuristic, a compound is 
more likely to be efficiently absorbed from the GI tract if at least 
three of the following are true: 
•  The molecular weight is not more than 500daltons 
•  There are five or fewer hydrogen bond donor groups 
•  There are ten or fewer hydrogen bond acceptor groups (gener-
ally nitrogens and oxygens) 
•  The octanol water partition coefficient is not greater than 10
5 
  Alternative heuristics have gained acceptance among chemists, 
such as the one based on the computation of total polar surface area 
(tPSA) [7,8]. Many of these methods can be viewed as alternative 
formulations of the Lipinski criteria; for example, the tPSA of a 
compound is a function of its molecular weight and the number of 
hydrogen bond donors and acceptors. These computational methods 
are generally applicable only to drugs that are passively absorbed 
by the transcellular route (see below). Hybrid models combining 
empirical and computational methods are also used [9]. 
  The gut permeability profile is variable among individuals; it 
varies with age and is subject to alterations due to pathological 
situations, such as inflammatory bowel disease (IBD), various ge-
netic diseases, and irritable bowel syndrome (IBS). In that context, 
the notion of a strictly non-absorbed drug is elusive; a finite fraction 
of the drug, as parent compound, metabolites, or impurities will 
inevitably be absorbed and disposed of systemically; notwithstand-
ing all efforts to minimize drug intake, only empirical pharmacol-
ogy and toxicology methods will determine whether the drug is safe 
and well tolerated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Mode of action of non-absorbed drugs. Class I: sequestering agent (exemplified by an anion-exchange polymer); Class II: Ligands of soluble intes-
tinal enzymes; Class III: exogenous enzymes; Class IV: Minimally absorbed and rapidly metabolized drugs (also referred to as soft drugs); Class V: Ligands of 
apical targets. (The modes of action of each class are described in the text) 1436    Current Pharmaceutical Design, 2012, Vol. 18, No. 10  Dominique Charmot 
4. NON-ABSORPTION CRITERIA ACROSS CLASSES OF 
NON-ABSORBABLE DRUGS 
  The criteria used to characterize the pharmacokinetic profile of 
a non-absorbed drug are essentially the same as those used for the 
absorption, distribution, metabolism, and excretion (ADME) profile 
of bioavailable drugs, and consist of establishing drug and metabo-
lite levels in arterial blood, the portal vein, urine, and feces, as well 
as determining the tissue distribution. 
4.1. Sequestering Agents 
  Sequestering agents, also referred to as binding resins, are usu-
ally synthesized as crosslinked polymeric particles of various size 
and shape. When in contact with intestinal fluid, the resin swells 
allowing a reciprocal transfer of endogenous ions (K
+, HPO3
2-, or 
bile acids) with the counter ions contained in the resin (Na
+ or Cl
-
depending on whether the resin is a cation or anion exchange mate-
rial).These polymers are resistant to gut metabolism and are mostly 
recovered intact in the feces. 
  The systemic absorption of sequestering agents is minimized by 
controlling particle size and by minimizing the presence of soluble 
impurities. It is generally agreed that intestinal uptake of particles 
correlates negatively with particle diameter. Maximal absorption 
occurs with particles of 50 to 100 nm in diameter, while particles 
larger than 1 m are trapped in the Peyer’s patches and do not 
translocate to systemic circulation [10]; manufacturing processes 
are controlled to minimize the presence of particles in this size 
range. Soluble impurities mostly comprise oligomers entrapped 
within the polymer matrix, or degradation products. Because se-
questering agents (e.g. phosphate and bile acid binders) are typi-
cally dosed between 2 and10 g/day, a substantial quantity of impu-
rities could potentially be released into the luminal space; therefore 
washing polymers thoroughly to achieve a specified water soluble 
oligomer content (typically less than 0.1 weight%) is a necessary 
and often costly aspect of polymeric drug manufacturing processes. 
The methodology for characterizing plasma drug content is irrele-
vant as resins rarely appear as such in blood circulation and are not 
easily characterizable as a drug entity because of their very large 
molecular weight and polydisperse nature; more typically impuri-
ties and degradation products are first identified in stress-stability 
testing or in vitro metabolism studies and then monitored in plasma. 
However, the gold standard method remains radioactive labeling 
with
14C and measuring the distribution of the label in urine, feces, 
and body tissues; typically synthetic crosslinked resins are almost 
quantitatively recovered in the feces, with yields ranging from 82% 
[11] to 99% [12]. Certain sequestering materials are made of in-
soluble metallic inorganic materials that release soluble metallic 
salts (Fe, Mg, La), which can potentially be absorbed. Therefore 
accumulation of those metals in plasma and tissues is closely moni-
tored. 
4.2. Non-Absorbed Small Molecules 
  Most of the agents described in classes ii and iv are small mole-
cules. Their non-systemic profile is conveniently characterized by 
traditional drug metabolism pharmacokinetic methods, tracking 
parent drug and metabolites in blood, urine, and feces. Low or un-
detectable levels of drug and metabolites in serum do not necessar-
ily imply non-absorption; the portal vein and bile should be assayed 
for the presence of drug and metabolites to check for gut absorption 
followed by hepatic uptake and disposition in bile. Loperamide, an 
antidiarrheal agent with very low plasma levels, is extensively ef-
fluxed from the enterocytes but is nevertheless present in the intes-
tinal wall [13] and partly eliminated from systemic circulation via 
hepatic uptake and excretion virtually intact in the feces. The pre-
clinical transport findings for enterocyte efflux mechanisms may 
not translate to a non-systemic profile in humans because of species 
differences in transporter expression, substrate affinity, physiologi-
cal function, and interplay between transporters and enzymes [14]. 
Ideally a non-systemic drug should be virtually absent in blood and 
urine, and the parent + metabolites should be recovered quantita-
tively in the feces. In reality, non-systemic drugs have a low but 
finite exposure in systemic compartments, from single to double 
digits ng/mL. Fecal recovery varies widely, from 0% for exogenous 
peptides or protein (due to extensive proteolytic degradation by host 
and bacterial proteases) up to 97% for the non-systemic antibiotic 
rifaximin [15]. As evidenced by radiolabel ADME studies [16], 
even in favorable cases mass balance studies often result in less 
than 100% recovery due to experimental limitations. 
  Historically, non-absorbable small molecule therapeutics were 
designed to selectively hit an intestinal target, but were not specifi-
cally engineered to be impermeable to the gut epithelia. Many of 
these compounds were discovered serendipitously by screening 
natural products, as was the case for or list at (lipase inhibitor), 
acarbose (-glucosidase inhibitor), and several antibiotics (oral 
vancomycin, rifaximin) of bacterial or fungal origin. The structural 
requirements imposed on small molecules to prevent diffusion 
across the intestinal lining, are clearly different and much more 
stringent than those of large crosslinked polymer particles physi-
cally segregated to the intestinal lumen. Small molecules have di-
mensions similar to those of substrates involved in molecular up-
take mechanisms (transporters and efflux pumps), and those of 
pores within TJs. 
  Lipinski’s rule was designed to be predictive of solute passive 
transport through the lipid bilayer of enterocytes; designing com-
pounds outside of Lipinski’s rule would prevent transcellular trans-
port. However, these rules do not address the passive diffusion 
pathway through the TJs or transporter-mediated absorption. There-
fore, the more stringent criteria for non-systemic drugs requires not 
only designing molecular structures outside of the Lipinski’s rule 
but also avoiding structures that are recognized by intestinal trans-
portersor subject to passive diffusion through the TJs. 
  Recent progress in identifying the diffusion mechanisms 
through the TJs has provided some insight about solute require-
ments for permeation. Tight junction permeability experiments 
have revealed a high capacity pathway for solutes less than about 
0.4 nm in radius [17] mediated by claudin proteins, and a second 
pathway, permeable to molecules with molecular weights up to 
several kg/mol. The latter pathway is due to time-dependent open-
ings in the otherwise continuous mesh of adherent TJ proteins 
(claudins, occludins, and junction-adhesion-molecules) [18]. In 
addition to the maximum size threshold imposed by the TJ pore 
distribution, it appears that the charge density and rigidity of the 
solute (here the drug molecule) tightly regulate passage across TJs. 
This area has been thoroughly investigated for enhancing TJ per-
meability to therapeutic peptides [19]. A survey of the mechanisms 
involved is out of the scope of this review. We note only that per-
meability does not necessarily correlate with molecular weight, and 
seems to better correlate with molecular cross-sectional diameter, or 
volume. Intuitively solute charge density might be thought to play a 
role in TJ permeation; however, recent studies with polypeptides of 
controlled charge density concluded it is unimportant [19]. 
  Taken in the context of non-systemic drugs, this would imply 
that molecules with high charge density and low flexibility would 
have low TJ permeability, and therefore limited paracellular diffu-
sion. 
  The exact nature of the paracellular diffusion has yet to be elu-
cidated and more research is required to establish precise structural 
requirements for non-systemic molecules. The field is nascent and 
the collection of non-systemic drugs too limited to train a Lipinski-
like heuristic model for non-systemic drugs. General recommenda-
tions can be made based on the emerging knowledge on TJ trans-
port mechanisms; however, only an experimentally based approach 
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5. PHARMACOKINETIC-PHARMACODYNAMIC RELA-
TIONSHIP IN NON-ABSORBED DRUGS 
  The pharmacokinetic-pharmacodynamic relationship is the 
“temporal aspects of drug action, and particularly the relationship 
between the concentration of drugs (and their active metabolites) in 
plasma or other biological fluids and their intensity and time course 
of their pharmacological effects” [20]. For non-systemic drugs, 
other biological fluid refers to the intestinal lumen, a body com-
partment rarely explored in drug development. However under-
standing the pharmacokinetic-pharmacodynamic relationship is 
critical for optimizing drug performance, dosage regimen, and for-
mulation. For example, agents blocking absorption or digestion of 
dietary components must be bioavailable in the upper part of the gut 
and provide optimal exposure to the gut target, whether apical or 
luminal. As opposed to systemic targets continuously perfused by 
biological fluids and drug at relatively constant composition, the 
lumen of gut is highly heterogeneous with pockets of fluids re-
vealed by magnetic resonance imaging (MRI) techniques [21] that 
show rapid changes in luminal free water as a function of diet com-
position or bowel disorders [22]. For non-systemic small molecule 
drugs, interaction with chyme components can reduce drug avail-
ability and potency [23], a situation analogous to that of systemic 
drugs binding to plasma proteins. Finally the role of the mucus 
layer on drug transient accessibility to the epithelia surface remains 
poorly understood. 
6. THERAPEUTIC APPLICATIONS OF NON-SYSTEMIC 
DRUGS 
6.1. Mineral Metabolism Disorders 
6.1.1. Phosphate Lowering Drugs 
  Patients with declining kidney function progressively lose the 
ability to excrete phosphate renally. The ensuing positive phospho-
rus balance triggers a hormonal response via FGF-23, parathyroid 
hormone (PTH) and active vitamin D. High-normal serum phospho-
rus elevates PTH which in turn induces bone resorption, causing 
phosphorus release, thus creating a vicious cycle resulting in secon-
dary hyperparathyroidism. This hormonal imbalance and concomi-
tant phosphorus overload result in an increased risk of vascular 
calcification, a risk factor for cardiovascular events, which are 
highly prevalent in chronic kidney disease (CKD) patients. 
  The first phosphate binder was aluminum carbonate, which 
sequesters dietary phosphate in the gut as insoluble aluminum 
phosphate salts. Because of its toxicity, aluminum was later re-
placed by calcium (acetate and carbonate salts), now generic drugs 
used in phosphate management for CKD. However, systemic ab-
sorption of calcium has fueled a controversy on the use of those 
agents, as vascular calcification is major risk for CKD patients. 
Sevelamer (RenaGel®; Genzyme-Sanofi), the first non-metallic 
based phosphate binder, was introduced to the market in 2000 for 
the normalization of serum phosphorus in dialysis patients. It is a 
crosslinked polyallylamine gel, binding phosphate via a combina-
tion of electrostatic and hydrogen bond interactions. The binding 
efficacy is approximately 0.5 mmol/g of polymer as calculated from 
a phosphorus balance study in humans [24]. Sevelamer also binds 
bile acids, thus reducing low-density lipoprotein (LDL) cholesterol 
levels via induction of bile acid biosynthesis from the cholesterol 
pool. Other phosphate binding agents based on synthetic polymers 
or inorganic salts (Mg, Fe) have been developed [25] in an effort to 
improve the selectivity and capacity with a goal of reducing the 
dose burden, currently the main obstacle to patient compliance. 
Bixalomer (Amgen/Astellas) is a next generation phosphate binder 
composed of microspheres of a crosslinked polyamine polymer, 
with a pore size optimized to selectively bind phosphate while 
minimizing fatty acid and bile acid uptake [26,27]. 
  The suboptimal clinical efficacy of phosphate binders is caused 
in part by competition from active intestinal phosphate transport. A 
radically different approach involves the development of phosphate 
transport inhibitors targeting the intestinal sodium/phosphate co-
transporter NaP2b (SLC34A3). NaP2b is expressed throughout the 
upper GI tract and mediates about half of dietary phosphate uptake 
[28]. Because NaP2b is expressed in other tissues, it is imperative 
that the inhibitor be non-absorbed and maintained within the intes-
tinal lumen. In one report, non-systemic NaP2b inhibitors (Amgen) 
were shown to reduce gut absorption of phosphate in rats [29].In 
another study, non-absorbable NaP2b inhibitors (Ardelyx) used 
alone or in combination with a phosphate binder were evaluated in 
two animal models: in an adenine-induced CKD rat model, 
NTX1942 reduced uremic biomarkers (serum concentration of 
phosphorus, creatinine and BUN), as well as parathyroid hormone 
and FGF-23 plasma levels; in a 5/6
th nephrectomy rat model, it 
delayed deterioration of renal function and, after 50 days of treat-
ment, showed a significant increase in survival outcome (Gehan-
Breslow-Wilcoxon curve comparisons) compared to vehicle-treated 
cohort [30]. Although those results are very preliminary they are 
consistent with the prominent role of body phosphorus in the eleva-
tion of FGF-23 and its causal role in the pathogenesis of left ventri-
cle hypertrophy contributing directly to high rates of cardiovascular 
mortality in individuals with CKD [31]. As the clinical dose would 
likely be substantially lower than that of phosphate binders, this 
new class of phosphate lowering drugs could provide a much 
needed phosphate reduction in the broader pre-dialysis CKD patient 
population. 
6.1.2. Potassium Lowering Drugs 
  Hyperkalemia is characterized by serum potassium higher than 
5.5 mmol/L, and can be an acute life-threatening condition if not 
quickly resolved. Hyperkalemia is common in CKD patients as 
their urinary potassium excretion is impaired. The risk is notably 
increased with the use of renin-angiotensin-aldosterone-system 
(RAAS) blockade drugs to treat hypertension and/or heart failure. 
Angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers and mineralocorticoid receptor antagonists all reduce renal 
sodium reabsorption via down regulation of the epithelial sodium 
channels (ENaCs) with a concomitant potassium-sparing effect 
leading to chronic hyperkalemia. Non-absorbed potassium binding 
drugs have long been used to treat acute hyperkalemia; they consist 
of sulfonated crosslinked resins neutralized with either sodium ions 
(Kayexalate®) or calcium ions (Sorbisterit®, Ca-Resonium®, Ar-
gamate®). They act as cation exchangers substituting Na
+ or Ca
2+ 
for K
+ in the lower GI tract, thereby draining potassium from sys-
temic circulation. By binding potassium in the lumen of the colon, 
those polymers create a steeper K
+ electrochemical gradient at the 
colonic epithelia, enhancing mucosal transport via potassium chan-
nels expressed apically at the mucosal surface [32,33]. These resins 
were not originally designed as non-absorbable drugs but were 
merely re-formulated from existing industrial grade cation-
exchange resins. They present as irregularly shaped particles, mixed 
with sorbitol, an osmotic laxative, to favor transit and mitigate con-
stipation. Cases of intestinal necrosis, which may be fatal, and other 
serious gastrointestinal adverse events (bleeding, ischemic colitis, 
perforation) have been reported in association with Kayexalate use 
[34]. The reason for those serious GI side-effects is unclear, but one 
could invoke the irregular shape of the particles that could induce 
micro-laceration of the mucosa, and also the particle suspension 
shear-thickening flow behavior leading to impaction. The main 
shortcomings of these resins are their modest in vivo binding capac-
ity and selectivity. The patient is thus required to take dozens of 
grams per day, causing many GI side effects for a modest benefit. 
Recently a crosslinked poly--fluoroacrylic acid polymer calcium 
salt with higher capacity and better physical properties [35,36] was 
developed to improve efficacy and patient compliance. Super-
absorbent materials based on crosslinked polyacrylic acid to bind 
either potassium or sodium by adjusting the Na
+/K
+/H
+cation com-
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with luminal fluid so is also capable of removing fluids in patients 
with fluid overload [37]. Cation binding selectivity remains a chal-
lenge since polymeric anion-exchangers have greater affinity for 
divalent cations (Ca
2+, Mg
2+) than for monovalent cations (Na
+, 
K
+), thus greatly reducing the potassium binding efficiency in the 
colon. For that reason, composite particles were designed, compris-
ing a cation-exchange polymer particle (crosslinked poly--
fluoroacrylate) with the surface covered by a thin pellicle of a sec-
ond polymer (crosslinked polyvinylamine). The shell polymer is 
permeable to monovalent ions such as K
+, but impermeable to diva-
lent cations (Ca
2+). Such core-shell particles increase the in vivo 
binding capacity for potassium compared to regular non-core-shell 
resins [38]. 
6.1.3. Treatment of Sodium Overload 
  Fluid and sodium overload are symptomatic of hypertension, 
congestive heart failure (CHF), and CKD. Insufficient cardiac out-
put and/or kidney failure triggers activation of RAAS, which then 
cascades into hypertension and cardiovascular and renal damage. 
Hypertension is tightly related to sodium homeostasis; decades of 
clinical trials have demonstrated the link between sodium intake 
and blood pressure. A 3 g/day reduction in salt intake decreases 
systolic and diastolic pressure by 5 and 2 mm Hg, respectively, 
leading to notable reductions in hypertension-related morbidity and 
mortality. 
  More than 80% of CKD patients are hypertensive and salt-
sensitive, aggravating the decline of kidney function. To manage 
their hypertension CKD patients are given ever increasing doses 
and combinations of RAAS inhibitors and diuretics. As kidney 
function declines, thiazide diuretics lose efficacy causing physi-
cians to treat with increasing doses of loop diuretics, ultimately 
resulting in an acceleration of kidney function decline. Moreover, 
excess dietary sodium limits the benefit of RAAS blockade drugs 
[39]. Sodium overload is also a hallmark of CHF patients with con-
comitant renal impairment, i.e. cardiorenal syndrome. 
  There are almost no literature reports of non-systemic agents 
that alleviate sodium overload by sequestering sodium in the gut. A 
few studies in the 1950s tested the ability of cation-exchange resins 
to resorb edema in heart failure patients [40,41]. The challenge is 
practically insurmountable given: i) the amount of sodium to re-
move coupled with the modest in vivo binding capacity of regular 
cation-exchange resins at colonic pH; ii) the release of one equiva-
lent of K
+ or Ca
2+for every bound Na
+; and iii) the rapid cation 
exchange of Na
+ for K
+ occurring in the colon as a result of the 
greater concentration of K
+ in the lower GI tract (vide supra). 
  Recognizing that the main pathway for sodium re-import pre-
sent throughout the GI tract is the Na/H antiporter 3 (NHE3) has led 
to the development of highly potent and non-systemic NHE3 inhibi-
tors as an alternative approach to managing sodium overload. Rep-
resentative of this class is RDX5791, a molecule that modulates the 
uptake of intestinal sodium from dietary or endogenous sources. 
Preclinical data in the rat indicate that NHE3 blockade shifts so-
dium almost entirely from urinary to fecal excretion. To further 
validate its therapeutic use in the setting of hypertension in CKD, 
RDX5791 was tested in five-sixths nephrectomized rats fed a high 
sodium diet. NHE3 inhibition reduced blood pressure, normalized 
albuminuria, and delayed heart and kidney damage [42]. 
6.1.4. Iron Overload 
  In hemochromatosis patients, abnormal dietary iron absorption 
leads to iron deposition in vital organs, including the liver, endo-
crine glands, heart, and skin. The most common form is hereditary 
and is due to mutation of the HFE gene that controls intestinal iron 
transport proteins (ferroportin and hepcidin). Treatment consists of 
twice weekly phlebotomy. A typical diet contains 10 to 20 mg of 
iron, of which only 1 to 2 mg are absorbed as non-heme iron (i.e. 
not complexed with heme component of hemoglobin) and heme-
iron. The standard of care employs systemic iron chelators, in-
jectable (deferoxamine; Desferal®) or orally administered (defera-
sirox; Exjade®). However, these compounds are associated with 
either a narrow therapeutic window (deferoxamine) or pose a risk 
of fatal renal failure and cytopenia (deferasirox). This provides a 
rationale for developing non-systemic gut-acting iron chelators. 
These are derived from structures typical of siderophores (hexaden-
tate chelates of catecholamide, hydroxamate, hydroxypyridonate, 
2,3-dihydroxyterephthalamide) that are made insoluble by function-
alization onto polymeric backbones [43]. However, there are few 
examples of non-systemic iron chelators demonstrating an effect in 
preclinical iron overload models [44] and no clinical development 
has been reported. One challenge encountered by this approach is 
the multiple pathways utilized by the intestinal mucosa to extract 
dietary iron, one of which is the selective transport of heme-iron 
[45]. This perhaps calls for a multivalent polymeric drug with dual 
binding sites specific to heme and non-heme iron. 
6.2. Non-Systemic Drugs for Treatment of Metabolic Diseases 
  This section encompasses non-systemic approaches to limit or 
delay absorption of nutrients (via inhibition of gastric lipase, -
glycosidase), cholesterol or bile acids (via inhibition of Niemann-
Pick C1-Like 1 [NPC1] or Ileal bile acid transporter [IBAT], or 
binding of intestinal bile acid), or altering energy utilization (via 
inhibition of pancreatic phospholipase A2 [PLA2]). 
6.2.1. Pancreatic Lipase Inhibitors 
  Orlistat (Xenical®) isa potent pancreatic lipase inhibitor iso-
lated from the bacterium Streptomyces toxytricini; it partially inhib-
its the conversion of dietary fat into fatty acids, thereby reducing fat 
absorption as only fatty acids are systemically absorbed from the GI 
tract. The undigested fat is eliminated in the feces. 
  Orlistat is partially metabolized in the gut wall with two me-
tabolites appearing in plasma at 26 and 108 ng/mL. Eighty three 
percent of the parent compound (97% of the parent + metabolites) 
is found in the feces [46]. In clinical trials, obese patients treated 
with orlistat in addition to lifestyle modifications lost a modest 2 to 
3 kg more than those treated with placebo [47]. The main side ef-
fect was steatorrhea (oily stools). Alizyme / Takeda are developing 
a close analog of orlistat, cetilistat, claimed to elicit fewer episodes 
of steatorrhea. Non-systemic polymeric lipase inhibitors were de-
veloped by GelTex Pharmaceuticals [48], to be combined with fat-
scavenging polymers [49], i.e. lightly crosslinked polyacrylate co-
polymers with cationic and hydrophobic moieties. Such polymers 
would either bind or adsorb at the surface of undigested fat droplets 
to prevent coalescence, thus minimizing steatorrhea. 
6.2.2. -Glucosidase Inhibitors 
  Acarbose (Precose®) is a complex oligosaccharide obtained 
through fermentation by Actinoplanesutahensis. It is an inhibitor of 
pancreatic alpha-amylase and membrane-bound intestinal alpha-
glucoside hydrolase enzymes. Taken with a meal, it partially inhib-
its digestion of dietary polysaccharides into glucose, therefore de-
laying glucose absorption and blunting post-prandial serum glucose 
excursion. Prescribed in pre-diabetic patients, itreduces the level of 
glycated hemoglobin A1c (HbA1c), a measure of sustained hyper-
glycemia. A radiolabel study demonstrated that about 35% of the 
drug is absorbed while only 2% of the parent compound is found in 
serum. Acarbose is metabolized within the GI tract, mostly by in-
testinal flora. In addition to its effect on post-prandial glycemia, 
acarbose also seems to induce GLP-1 secretion via a glucose-
mediated stimulation of entero-endocrine cells distally in the gut, 
potentially contributing to its anti-diabetic effect. The downside of 
delayed glucose absorption is frequent GI side effects arising from 
colonic fermentation of glucose. 
6.2.3. Cholesterol Transport Inhibitors 
  Ezetimibe (Zetia®) inhibits intestinal cholesterol absorption, 
leading to upregulation of LDL-receptors on cell surfaces and in-
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plasma levels of LDL, a biomarker of atherosclerosis and cardio-
vascular events. The target of ezetimibeis NPC1, [50], a protein 
apically expressed in the upper GI tract characterized as a trans-
porter of sterols including cholesterol [51], and probably other 
sterol-based metabolites such as vitamin D3 [52]. Ezetimibe is ab-
sorbed and extensively glucuronidated to ezetimibe-glucuronide, 
which has greater activity than the parent compound. Both the par-
ent and its glucuronide adduct are excreted in the bile and undergo 
extensive entero-hepatic cycling upon de-glucuronidation and re-
absorption. According to criteria presented above in Classification 
of Non-Absorbed Drugs, Ezetimibe does not strictly meet the crite-
ria of a non-systemic drug since the parent drug and its main me-
tabolite are present in plasma at substantial levels and likely act on 
hepatic NPC1 localized on the bile canalicular membrane. Whether 
ezetimibe may induce mechanism-based side effects due to its role 
in cholesterol homeostasis in the liver is unclear; however, the 
clinical safety profile of ezetimibe appears adequate. Several com-
panies have been working to develop second-generation non-
systemic NPC1 inhibitors by creating isosteric analogs of glucuron-
idatedezetimibe, substituting the O-glycoside moiety with C-
glycoside or aglycon groups resistant to glycosidases and polar 
enough to prevent drug absorption [53-59]. In general this new 
class of NPC1 inhibitors achieves excellent potency against their 
target (nM range) with low systemic exposure; however, the clini-
cal data are disappointing. As of November 2011, AstraZeneca and 
Sanofi-Aventis reported suboptimal efficacy compared with 
ezetimibe and abandoned further development [55,56] . Kotobuki 
Pharmaceutical Co is still conducting phase II studies in the United 
Kingdom. It is possible that the lower efficacy results from a lack of 
target exposure during postprandial conditions, in contrast with 
ezetimibe which has the great advantage of being constantly recy-
cled at the mucosa surface via entero-hepatic cycling. 
6.2.4. Bile Acid Binders 
  The first generation of bile acid binders is embodied by cho-
lestyramine, a crosslinked polystyrene resin functionalized with 
quaternary ammonium groups. It sequesters bile acids in the GI 
tract and up-regulates bile acid biosynthesis from circulating cho-
lesterol, lowering plasma LDL-cholesterol. To achieve significant 
LDL-cholesterol reduction, 5 to 25 g of resin per day is needed, 
clearly limiting patient compliance. In the distal segment of the 
ileum, bile acids are avidly re-absorbed by the IBAT, thus limiting 
the efficacy of bile acid resins, a situation analogous to that of 
phosphate binders competing with the NaP2b phosphate trans-
porter. Researchers at GelTex / Genzyme rationally designed ter-
polymers with a careful balance of cationic and hydrophobic groups 
to increase affinity to bile acids [60]; as important as binding capac-
ity is that the polymer retain bile acids past the ileal segment, where 
free bile acids drop drastically as a result of IBAT-mediated bile 
acid re-uptake. The resulting drug, colesevelam (Welchol®), is 
significantly more potent than cholestyramine in lowering LDL-
cholesterol. Anecdotally, sevelamer, a phosphate binder composed 
of a hydrophilic crosslinked polyaliphatic amine, has an LDL low-
ering capacity close to colesevelam’s, which could be easily ex-
plained by the co-binding of fatty acids and bile acids forming a 
tight complex [61]. In clinical studies, bile acids binders such cole-
sevelam and colestilan showed a modest but significant diminution 
of HbA1c, stimulating a debate on the origin of the effect [62]. A 
plausible mechanism is that bile acids leak from the complex poly-
mer / bile acid and induce GLP-1 secretion via stimulation of TGR5 
receptors in colonic L cells. 
6.2.5. IlealBile Acid Transport Inhibitors 
  To achieve drastic LDL-reductions in people at risk for cardio-
vascular events, such as type 2 diabetic patients, high doses of stat-
ins (HMG-CoA reductase inhibitors) must be administered; how-
ever, the mechanism-based toxicity of statins (myopathy and rhab-
domyolysis) strongly limits this approach. Combination approaches 
using orthogonal mechanisms to maintain LDL under guideline 
levels are preferred. In this context, IBAT inhibitors were actively 
pursued in the 1990s as an alternative to bile acid binders with the 
goal of reducing the dose and circumventing vitamin mal absorp-
tion, a common side-effect of bile acid sequestrants. IBAT inhibi-
tors selectively inhibit the re-uptake of bile acids in the ileum, in-
creasing fecal elimination and triggering biosynthesis of biliary 
salts from the cholesterol pool. Several companies worked to de-
velop such inhibitors, and for the first time utilized a rationalized 
discovery effort for non-absorbable compounds. Potent molecules 
were developed based on bile acid pharmacophores and synthetic 
chemotypes including benzothiazepine, propanolamines, 4-phenyl-
quinolines, and lignans, among others. The concept of kinetophore 
was introduced; a structural unit violating Lipinski’s rule was teth-
ered to the pharmacophore moiety via a linker, making the whole 
molecule large and polar while maintaining potency and solubility 
[63]. 
  Kinetophores were selected from short peptides, sugars, and 
quaternary ammonium-capped polyethylene-oxides groups. Su-
pramolecular structures comprising two or three copies of the in-
hibitory units were also proposed (i.e. dimer and trimer of bile acid 
mimics). Although preclinical data were encouraging, showing 
significant reduction in LDL levels in hamsters, clinical data have 
been limited or disappointing, showing relatively modest reductions 
in LDL, and diarrhea side effects at doses providing the maximal 
LDL lowering effect. Diarrhea is not unexpected as the presence of 
bile acids in the colon is known to elicit a pro-motility and prose-
cretory effect. The modest efficacy in the presence of GI side ef-
fects has stopped all clinical development of IBAT inhibitors for 
the treatment of hypercholesterolemia; no clinical developments 
have been reported since 2001. Recently, GlaxoSmithKline showed 
that in a diabetic rat model, the benzothiazepine IBAT inhibitor 
264W94 increases bile acids in the distal intestine, promoting the 
release of the endocrine peptide GLP-1 and its accompanying sati-
ety and energy expenditure signaling, improving HbA1c and insulin 
signaling [64]. 
6.2.6. Phospholipase A2 IBInhibitor 
  The digestion of dietary and biliary phospholipids by pancreatic 
phospholipase A2 IB (PLA2 IB) is considered a necessary step in 
cholesterol absorption; studies with PLA2 IB inhibitors or PLA2 IB 
knock-out mice showed a delay in cholesterol uptake [65,66]. Nev-
ertheless compensatory mechanisms have limited the pharmacol-
ogical impact of PLA2 inhibition by this approach. More recently, 
pharmacological or genetic blockade of PLA2 IB revealed a new 
potential for treatment of obesity and diabetes. Lysophospholipids 
produced by PLA2 IB hydrolysis suppress hepatic fat utilization 
and down-regulate energy expenditure [67,68]; the PLA2 IB inhibi-
tor methyl indoxam effectively suppresses diet-induced obesity and 
diabetes in mice [69]. Dimeric PLA2 inhibitors with minimal bio-
availability were optimized based on the methyl indoxam pharma-
cophore, and preclinical data on rodent models were reported in the 
patent literature [70]. 
6.3. Binding or Neutralizing Intestinal Toxins 
6.3.1. Clostridium difficile Toxin Binder 
 Clostridium  difficile  (CD) is a gram-positive bacterium respon-
sible for many cases of antibiotic-associated colitis (CDAD) 
[66,71,72]. Toxigenic strains of C. difficile produce two exotoxins, 
toxin A and toxin B, with toxin A generally accepted as the primary 
toxin responsible for producing clinical symptoms [73]. It is a 
nosocomial disease; patients acquire the organism from hospital 
medical staff and the contaminated environment [74]. The major 
challenge in therapy is in the management of patients with multiple 
relapses, where antibiotic control is problematic. 
  Several approaches have been reported for directly neutraliz-
ingCD toxin activity in the intestinal tract using multi-gram quanti-
ties of anion exchange resins (cholestyramine, colestipol). Cho-1440    Current Pharmaceutical Design, 2012, Vol. 18, No. 10  Dominique Charmot 
lestyramine, a cationic resin that binds to C. difficile toxins, has 
been used as a treatment for C. difficile colitis in some patients. 
This resin has shown only modest activity and is not recommended 
for use in patients with severe cases of C. difficile colitis. Cho-
lestyramine also binds to vancomycin and must be dosed separately 
if it is used in combination with this antibiotic. In a rat ileum CD 
toxin A challenge assay, cholestyramine showed weak activity 
compared to for instance linear high molecular weight polystyrene 
sulfonate, the toxin binder developed by Geltex as Tolevamer [75]. 
The tolevamer-CD toxin A interaction is polyvalent and of rela-
tively high affinity, operating via a combination of electrostatic and 
hydrophobic forces [76]. 
  The structures of the CD toxins have been studied extensively 
[77], and four functional domains have been identified. The ‘B’ 
domain, also known as the binding C-terminal domain, has ele-
ments that bind specific sugars on the surface of enterocytes. Toxin 
A avidly binds to the trisaccharide Gal(1-3)Gal(1-4)GlcNAc. 
Paradoxically, this structure is found in most mammals, but not 
humans. It has been proposed that in human colon, the C. difficile 
bacterium secretes -fucosidase that converts the endogenous hu-
man sugars to the appropriate target. Whatever the mechanism, 
there is compelling evidence that binding these lectin-like proteins 
is a key first step in the endocytosis process essential for virulence. 
  A toxin A specific sorbent was prepared by attaching the recep-
tor epitope (trisaccharide Gal(1-3)Gal(1-4)GlcNAc) to the sur-
face of large aluminosilicate spheres. This material (synsorb) [78] 
was tested in patients but not pursued further because of the large 
dose and gritty nature of the beads. Later, the same epitope was 
anchored to the surface of polymeric nanoparticles. The spacing of 
the trisaccharide and the composition of the nanoparticle backbone 
were varied to enhance the polyvalent interaction and toxin neu-
tralization activity in vitro and in vivo [79]. Despite encouraging 
results in early clinical trials, neither synsorb nor tolevamer toxin 
binders had confirmed clinical efficacy in later stage development. 
Oral vancomycin, a low bioavailability gram positive antibiotic, is 
prescribed for recurring cases of CDAD; the long-awaited next 
generation, non-systemic gram positive antibacterial fidaxomicin 
[80] is an 18-membered macrocyclic antibacterial compound and 
has “minimal systemic absorption” according to its package insert; 
its main metabolite OP-1118, the hydrolysis product of the isobu-
tyryl ester, however, is detectable in the plasma of patients in the 
range 22-50 ng/ml. In clinical trials, fidaxomicin was no less effec-
tive than vancomycin in the treatment of C. difficile infection, based 
on non-inferiority analyses of clinical cure rates. The rate of recur-
rence, a hallmark of C. difficile infection, was significantly lower 
with fidaxomicin than with vancomycin therapy in patients infected 
with non-NAP1/BI/027 strains (8.4% vs 25.3%), but not signifi-
cantly different in patients infected with the NAP1/BI/027 strain 
(23.3% vs. 31.2%) [81]. 
6.3.2. Detoxification of Enteral Lipopolysaccharides 
  Only recently has the pivotal role of bacterial endotoxin been 
recognized in the etiology of GI diseases. An abnormally permeable 
gut mucosa allows slow infusion of lipopolysaccharides (LPS) from 
the lymph nodes and portal vein into key organs such as the liver. 
Mild endotoxemia due to LPS at concentrations orders of magni-
tude lower than those encountered in septic shock, is now hypothe-
sized to be a risk factor in IBD [82], non-alcoholic-steatohepatitis 
(NASH) [83], insulin resistance [84], chronic heart failure [85], and 
progression of AIDS [86]. 
  Although IBD is a multifactorial disease that cannot be reduced 
solely to the effect of LPS, the detoxification of luminal LPS has 
produced interesting results. In a small pilot clinical study, IBD 
patients with ulcerative colitis were treated by duodenal infusion of 
bovine alkaline phosphatase, an LPS dephosphorylating agent, with 
an encouraging resolution of symptoms [87]. 
 
6.3.3. Detoxification of Gluten in the Treatment of Celiac Disease 
  In genetically susceptible patients, exposing the small intestine 
to gluten induces a CD4+ T-cell mediated inflammatory response, 
leading to destruction of the intestinal villous structure. The princi-
pal toxic components of wheat gluten belong to a family of closely 
related proline and glutamine rich proteins called gliadins [88]. 
Non-absorbable copolymers of hydroxyethyl methacrylate and 4-
styrenesulfonate have been proposed to neutralize luminal gliadin 
[89], but the most advanced approach utilizes glutenases to selec-
tively digest these immunogenic peptides in the upper gut [90]. One 
combination of these proteases, ALV003 (Alvine Pharmaceuticals), 
is currently in phase II clinical development, and preliminary re-
sults show biopsy proven clinical efficacy in celiac disease patients 
[91]. 
6.3.4. Restoring Gut Integrity via Modulation of Tight Junction 
Permeability 
  AT-1001 (Alba Therapeutics) is an octapeptide derived from 
zonula occludens toxin (ZOT), a prokaryotic protein secreted by 
Vibrio cholerae that appears to bind to a receptor on the apical sur-
face of enterocytes. AT-1001 inhibits gliadin-induced intestinal 
epithelial cell cytoskeleton rearrangement and TJ disassembly. Pre-
treatment with the peptide blocks gliadin-induced leak in diseased 
(celiac) human duodenal epithelia [92]. In a double-blind placebo-
controlled safety study in celiac disease subjects, AT-1001 was 
undetectable in plasma and appeared to reduce intestinal barrier 
dysfunction [93]. 
6.3.5. Uremic Toxin Binders 
  The uremic syndrome is attributed to progressive retention of a 
large number of toxins, which under normal conditions are excreted 
by the healthy kidneys. Some of these toxins originate from the 
diet, and thus can be targeted by non-absorbable materials with 
affinity towards those toxins. Indoxyl sulfate and cresyl sulfate are 
toxins generated in the intestine and liver by first-pass metabolism 
of indole and cresol, which are formed upon digestion of dietary 
tryptophan and tyrosine, respectively. Indoxyl sulfate promotes 
progression of glomerular sclerosis and CKD in vivo [94-96] via 
activation of the NF-B pathway, inducing cytotoxicity in renal 
proximal tubular cells [97]. AST-120 (Kremezin®) consists of 
high-surface area activated carbon particles, which given orally to 
CKD patients at 6 g/day reduces serum indoxyl sulfate [98] by ab-
sorb ingindole from the colon. It has been used in Japan since 1991 
to delay deterioration of renal function in CKD patients, although 
the clinical benefit is still unclear [99-101]. 
  A second class of toxins comprises advanced glycation endpro-
ducts (AGEs) formed in processed foods via the Maillard reaction 
[102]. Typical dietary AGEs are N-carboxymethyl-lysine and N-
carboxyethyl-lysine; their serum concentrations correlate with their 
dietary intake in uremic patients [103,104]. Recent studies report 
that AST-120 and sevelamer each decrease serum AGE levels in 
pre-dialysis CKD [105] or hemodialyzed patients [106] and imply 
that both drugs bind dietary AGEs in the gut. The vast range of 
toxins and their hypothetical role in renal pathology [107,108] pose 
a challenge for designing novel, more efficient toxin scavengers – it 
is unclear where future development should focus. Non-specific 
binding may be beneficial for sequestering an array of potential 
toxins; improved binding capacity remains critical to lowering the 
therapeutic dose. 
6.3.6. Treatment of Hyperoxaluria 
  In its most severe form, excessive urinary oxalate excretion 
(hyperoxaluria) is caused by a deficiency of the hepatic peroxiso-
mal enzyme alanine-glyoxylate aminotransferase (Agxt). 
Overproduction of oxalate may lead to recurrent kidney stones, 
progressive nephrocalcinosis, and loss of kidney function. Oxalate 
is partially eliminated by the GI tract acting as a sink for systemic 
oxalate; this effect is particularly pronounced in CKD [109]. An 
elegant therapeutic approach is to treat orally with crosslinked 
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decarboxylase that remain stable in the GI tract and efficiently me-
tabolize oxalate in the gut [110]. 
6.4. Normalization of Bowel Dysfunction 
  With a 15% prevalence in North America, chronic idiopathic 
constipation (CIC) is a significant burden on society [111,112]. 
Normal transit constipation is the most common form, but even 
within this population, segmental transit time within the colon can 
be variable [113] and the majority of patients had abnormally low 
small intestine motility [114]. Irritable bowel syndrome is a com-
mon GI disorder associated with alterations in motility, secretion, 
and visceral sensation. The most common form of IBS is the con-
stipation-dominant form, which causes abdominal pain as well as 
replicating most of the CIC symptoms. 
  The intestinal motor secretory reflex controls motility and intes-
tinal fluid content, ultimately driving transit. In the past few years, 
novel non-systemic approaches have emerged to selectively activate 
prosecretory pathways. Linaclotide (Ironwood Pharmaceuticals) is a 
close analog of the heat stable Escherichia coli enterotoxin, a potent 
agonist of guanylate cyclase receptor, which via cGMP production 
stimulates the cystic fibrosis transmembrane conductance regulator 
(CFTR) chloride channel. Linaclotide acts locally in the intestinal 
tract to induce secretion. It has a very short half-life in the GI tract 
and very low systemic exposure [115]. In multiple studies in CIC 
patients, linaclotide improved bowel habits and symptoms [116], 
and in a phase II study demonstrated statistically significant im-
provementsin abdominal pain and discomfort, as well as bowel 
normalization [117]. 
  RDX5791 (Ardelyx), a non-systemic NHE3 inhibitor described 
above, modulates the re-absorption of sodium and fluid in the upper 
GI and alters stool form [118], as was demonstrated in a multi-
ascending dose phase I study in healthy subjects [119]. Both 
RDX5791 and linaclotide demonstrated a pharmacological effect in 
a rat model of visceral hypersensitivity [120,121], a hallmark of 
IBS suggesting that an influx of intestinal fluid in the upper GI tract 
may elicit a neurohormonal signal mediating local anti-nociception. 
  Inhibitors of the IBAT reduce active ileal reabsorption of bile 
acids. This results in an increased concentration of bile acids enter-
ing the colon, stimulating colonic motility and secretion. Bile acids 
induce propulsive contractions in the human colon, and induce 
secretion through activation of adenylate-cyclase, increased mu-
cosal permeability, and inhibition of apical Cl
-/OH
- exchange. 
A3309 (Albireo), a selective inhibitor of the IBAT, increases stool 
frequency and reduced time to first stool. The most common side 
effects are abdominal pain and diarrhea [122]. Of note, the use of 
non-absorbable, luminally active dinucleotide mimics, such as 
EPX-16006 (Epix Pharmaceuticals), to trigger chloride secretion 
via stimulation of the colonic P2Y2 receptor has been shown to 
increase feces production and improve gastrointestinal motility in 
preclinical models [123]. 
7. OPPORTUNITIES FOR NON-SYSTEMIC DRUGS 
  Non-systemic drugs clearly have earned a place in the pharma-
copeia, treating important diseases with remarkably good safety 
profiles. The field is approaching a critical transition from its prior 
focus on niche polymeric materials that sequester intestinal small 
molecules to non-systemic agents targeting transporters and recep-
tors expressed at the intestinal epithelia. Proteomic analysis of 
membrane proteins lining the GI epithelia, or luminome, is in its 
infancy, but recent studies have revealed a vast repertoire of poten-
tial targets [124,125]. Approximately 45 transporters, 20 digestive 
enzymes, 105 signaling proteins, and 95 proteins were identified 
from preparations of brush border membranes isolated from murine 
jejunum. To fully exploit these findings, further work is needed to: 
i) determine the function and therapeutic potential of those proteins; 
ii) identify those effectively present at the apical pole; and iii) probe 
whether a non-absorbed molecule can modulate protein activity. 
  The remarkably rapid remission of diabetes in patients with 
Roux-en-Y by-pass surgery [126] has transformed our vision of the 
roles of these previously unidentified or unexplored hormones, 
receptors, and factors in the systemic regulation of metabolism 
[127, 128]. Examples of such receptors are TGR5 [129] and 
GPR119 [130], G-protein coupled receptors responding to bile ac-
ids and dietary lipids respectively, triggering secretion of GLP-1, 
and peptide YY (PYY) with pleiotropic effect across various path-
ways to restore insulin sensitivity and induce satiety. Non-systemic 
agents targeting one or more of these receptors would have a bene-
fit in the treatment of diabetes and metabolic diseases. 
  Host-gut flora interaction plays an important role in the etiology 
of some chronic GI disorders.Whether a non-systemic intervention 
could reverse diseases such as IBD or IBS is yet unclear, but these 
evolving fields point to intestinal transporters and receptors as pos-
sible factors mediating the disease. Protease-activated-receptor 2 
(PAR-2) expressed on the apical side of the GI tract are suspected 
of playing a key role in the pathology of diarrhea-predominate IBS 
(IBS-D) [131] and IBD [132]. These receptors are activated as a 
result of abnormal luminal protease activity in IBS-D patients. 
Colonic PAR-2 stimulation appears to be the primary event in TJ 
openings that increase GI permeability to flora antigens. Bacterial 
antigen translocations subsequently trigger an innate immune re-
sponse that cascades in further submucosal PAR-2 stimulation 
causing increased intestinal secretion (diarrhea) and nociceptive 
signaling to afferent neurons (pain). Non-absorbed PAR-2 antago-
nists could potentially restore mucosal integrity and resolve in-
flammation symptoms. 
  In IBD, the role of epithelial sensors to microbial products re-
sulting in increased immune stimulation, epithelial dysfunction, or 
enhanced mucosal permeability is now well established. Certain 
epithelial transporters (PepT1) [133,134] and receptors (Toll-like 
receptors) participate in sensing or translocating bacterial antigens 
[135] and could therefore constitute novel therapeutic targets. Final-
lynew safe and effective anti-diarrhea drugs are urgently needed in 
developing countries: the role of intestinal ion channels (CFTR, 
CaCC) and ion-sensors (Ca
2+-sensing receptor [136]) in the etiol-
ogy of secretory diarrhea and their apical presentation in the gut, 
make them attractive targets for designing non-absorbable agents 
with a high therapeutic index [137-139]. 
ABBREVIATIONS 
ADME  =  Absorption, distribution, metabolism, and 
excretion 
AGEs  =  Advanced glycation end products 
CFTR  =  Cystic fibrosis transmembrane conduc-
tance regulator 
CHF =  Congestive  heart  failure 
CIC  =  Chronic idiopathic constipation 
CKD  =  Chronic kidney disease 
FGF-23  =  Fibroblast growth factor 23 
GI =  Gastrointestinal 
GLP-1 =  Glucagon-like  peptide-1 
HbA1c  =  Glycated hemoglobin A1c 
HMG-CoA = 3-Hydroxy-3-methylglutaryl-coenzyme  A 
IBAT  =  Ileal bile acid transporter 
IBD  =  Inflammatory bowel disease 
IBS =  Irritable  bowel  syndrome 
IBS-D =  Diarrhea-predominate  IBS 
LDL =  Low-density  lipoprotein 
LPS =  Lipopolysaccharides 
NaP2b =  Sodium/phosphate  co-transporter   1442    Current Pharmaceutical Design, 2012, Vol. 18, No. 10  Dominique Charmot 
NHE3  =  Na/H antiporter 3 
NPC1  =  Niemann-Pick C1-Like 1 
PAR-2 =  Protease-activated-receptor  2 
PLA2 =  Phospholipase  A2 
PTH =  Parathyroid  hormone 
RAAS =  Renin-angiotensin-aldosterone-system 
TJ =  Tight  junction 
tPSA  =  Total polar surface area 
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